Patents Examined by Scott D. Priebe
  • Patent number: 7407801
    Abstract: The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by such vectors. The nucleic acid molecules, vectors and transformed host cells of the present invention are useful for treating a variety of genetic, metabolic and acquired diseases, including inter alia cystic fibrosis (CF) airway disease.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: August 5, 2008
    Assignees: University of Iowa Research Foundation, National Institutes of Health (NIH)
    Inventors: Lynda S. Ostedgaard, Michael J. Welsh, Mark F. Stinski, John A. Chiorini
  • Patent number: 7351697
    Abstract: The invention relates to a vector for the gene therapeutic treatment of tumors, especially in connection with radiotherapy. Said vector is provided with a therapeutic gene in the DNA sequence thereof. The gene is controlled by the promoter for the catalytic subunit of the telomerase or by the promoter for cyclin A.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: April 1, 2008
    Inventors: Jan-Heinerr Küpper, Ralph Meyer, Mirella Meyer-Ficca, Reinhard Kandolf
  • Patent number: 7344711
    Abstract: This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: March 18, 2008
    Assignee: Oncolytics Biotech Inc.
    Inventors: Ramon Alemany Bonastre, Manel Maria Piqueras
  • Patent number: 7341718
    Abstract: The present invention is related to compositions and methods for the delivery of nucleic acids to neurons in a mammal, and uses thereof. The present invention specifically discloses the use of compounds that cause synaptic nerve sprouting to increase neuron retrograde transport of a vector or a product (a polypeptide or a nucleic acid for example) in a mammal. The invention is also based on the use of a compound that interacts with synaptosomal associated proteins to increase neuron retrograde transport of a vector or a product such as one cited above in a mammal. The invention also relates to a product comprising a viral vector comprising a transgene and a compound that causes synaptic nerve sprouting, for sequential use for delivering said transgene to neurons by retrograde transport and its uses for the preparation of a composition used as a treatment in several neurological disorders.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: March 11, 2008
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Stéphanie Millecamps-Navarro, Martine Barkats, Jacques Mallet
  • Patent number: 7341710
    Abstract: The present invention provides methods for in vivo panning of a library to identify molecules that specifically home to a selected organ.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: March 11, 2008
    Assignee: The Burnham Institute
    Inventors: Erkki Ruoslahti, Renata Pasqualini
  • Patent number: 7341871
    Abstract: The invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest. In particular, the invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest in an age-related manner and/or in a liver-specific manner. The invention further provides methods of using the regulatory nucleic acid sequences provided herein for age-related and/or liver-specific expression of nucleotides seuqences of interest. The invention also provides host cells and transgenic non-human animals which harbor the regulatory nucleic acid sequences of the invention. The compositions and methods of the invention are useful in regulating expression of a nucleotide sequence of interest in an age-related and/or liver-specific manner.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: March 11, 2008
    Assignee: The Regents of the University of Michigan
    Inventors: Kotoku Kurachi, Sumiko Kurachi
  • Patent number: 7318919
    Abstract: Gene Therapy vectors, which are especially useful for cystic fibrosis, and methods for using the vectors are disclosed.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: January 15, 2008
    Assignee: Genzyme Corporation
    Inventors: Richard Gregory, Donna Armentano, Larry A. Couture, Alan E. Smith
  • Patent number: 7316924
    Abstract: Described herein are methods to enhance protein secretion in a host cell. In preferred embodiment, the host cell is a gram-positive microorganism such as a Bacillus. In another preferred embodiment, the host cell is a gram-negative microorganism. Preferably the gram-negative microorganism is an Escherichia coli or a member of the genus Pantoaea. Protein secretion may be enhanced by the overexpression of protein components of the Tat pathway. Alternatively, secretion of foreign proteins can be selectively enhanced by forming a chimeric polypeptide comprising a tat signal sequence and the protein of interest. In a preferred embodiment, the tat signal sequence is selected from phoD or LipA.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: January 8, 2008
    Assignee: Genencor International, Inc.
    Inventors: Sierd Bron, Jan D. H. Jongbloed, Joerg Muller, Jan M. Van Dijl
  • Patent number: 7306794
    Abstract: The invention provides a recombinant viral vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus, which portion is capable of infecting a hepatic cell; and a human VLDL receptor gene operatively linked to regulatory sequences directing its expression. The vector is capable of expressing the normal VLDL receptor gene product in hepatic cells in vivo or in vitro. This viral vector is useful in the treatment of metabolic disorders caused by the accumulation of LDL in plasma, such as familial hypercholesterolemia or familial combined hyperlipidemia.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: December 11, 2007
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Karen Kozarsky, Jerome Strauss, III
  • Patent number: 7297540
    Abstract: Methods of generating, and isolating adult stem cells and utilizing such cells and/or embryonic stem cells in generating tissue of a specific function and micro-architecture are provided.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: November 20, 2007
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventor: Eduardo N. Mitrani
  • Patent number: 7285542
    Abstract: Methods and compositions are provided for transgene expression in target cells. Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other gene of interest in mammalian host cells are provided, as well as methods therefor. Inducible expression of the transgenes at high levels under physiologic conditions results from induction by hyperthermic conditions relative to the basal temperature of the host cells.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: October 23, 2007
    Assignee: The Arizona Board of Regents on behalf of The University of Arizona
    Inventors: Tom Tsang, Eugene W. Gerner, David T. Harris, Evan Hersh
  • Patent number: 7273932
    Abstract: The invention relates to antisense oligonucleotides, in particular to antisense oligonucleotides to receptor genes, and the use of such oligonucleotides to regulate reproductive function and as chemopreventive or as a chemotherapeutic for various cancers, especially ovarian cancers. The invention also provides a method for preventing estrogen synthesis, a function of developing ovarian follicles, a therapeutic consideration for the prevention and treatment of some cancers of the breast, endometrium, ovary and cervix and of some endometriosis. The invention also relates to pharmaceutical compositions containing antisense oligonucleotides (ODNs, having 8 to 60 nucleotides) that act by binding to intracellular molecular targets. Optionally, for efficient delivery to a target DNA, RNA or protein, the ODNs may be covalently linked to a carrier moiety, which facilitates delivery of the ODN to the cytosol.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: September 25, 2007
    Assignee: The University of Cincinnati
    Inventors: Andrew R. LaBarbera, YiFang Wang, ChangHong Zhu
  • Patent number: 7262062
    Abstract: As anti-RNA polymerase (RNAP) antibodies are detected with high frequency in patients suffering from cutaneous scleroderma where skin sclerosis progresses rapidly, supervenes scleroderma renal crisis at a high rate, and associates with clinical entities whose prognoses are extremely bad, it is intended to provide a convenient method of detecting an anti-RNAP antibodies, which is extremely useful in diagnosing and classifying clinical entities of scleroderma, and predicting organ failure, in particular scleroderma renal crisis.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: August 28, 2007
    Assignee: Keio University
    Inventor: Masataka Kuwana
  • Patent number: 7261885
    Abstract: The invention provides an adenoviral vector comprising (a) at least a portion of an adenoviral genome comprising a major late transcription unit containing a terminal exon, wherein the terminal exon comprises a 5? splice acceptor DNA sequence element and a 3? polyadenylation signal sequence, and (b) a non-native nucleic acid sequence encoding a protein that does not contribute to the adenoviral vector entry into a host cell, wherein the non-native nucleic acid sequence is positioned within the terminal exon, such that the non-native nucleic acid sequence is selectively expressed in cells within which the adenoviral vector can replicate. The invention further provides an adenoviral vector composition and a method for treating or preventing a pathologic state in a mammal, comprising administering to the mammal the adenoviral vector composition of the invention in an amount sufficient to treat or prevent the pathologic state in the mammal.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: August 28, 2007
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Erik S. Falck-Pedersen, Jason G. D. Gall
  • Patent number: 7261886
    Abstract: An insect larva aerosol infection method for producing recombinant proteins and baculovirus bio-insecticides is disclosed. A liquid spray of budded form baculoviruses are employed to infect insect larvae in order to reduce the manpower for manual injections and the energy wasted in feeding infection technologies. The invention may be applied to the production of recombinant proteins and baculoviruses as the production platform for bio-insecticides.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: August 28, 2007
    Assignee: Council of Agriculture, Executive Yuan
    Inventors: Tzong-Yuan Wu, Suey-Sheng Kao, Tzyy-Rong Jinn
  • Patent number: 7261887
    Abstract: Methods for delivering potentially therapeutic or prophylactic protein and peptide agents to mammalian cells are provided. The agents are delivered by mutant trypanosomatid protozoa that have been genetically manipulated to code for such protein or peptide agents. The mutant protozoa additionally lack certain enzymes within the heme biosynthetic pathway, making the mutants susceptible to porphyria and eventual lysis.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: August 28, 2007
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventors: Kwang-Poo Chang, Shigeru Sassa, Jerome F. Sah, Hiroya Ito, Bala Krishna Kolli, Daniel A. Peterson
  • Patent number: 7256036
    Abstract: The invention relates to an adenovirus fiber modified by the mutation of one or more residues. The residues are directed towards the natural cell receptor in the three-dimensional structure of said adenovirus. The invention further relates to a DNA fragment, and expression vector, and a cell line expressing said fiber, and also concerns an adenovirus, the process for producing this type of adenovirus, and an infectable host cell, as well as their therapeutic application and a corresponding pharmaceutical composition.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: August 14, 2007
    Assignee: Transgene
    Inventors: Valérie Legrand, Majid Mehtali, Pierre Boulanger
  • Patent number: 7250404
    Abstract: A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: July 31, 2007
    Assignees: Vical Incorporated, Wisconsin Alumni Research Foundation
    Inventors: Philip L Felgner, Jon A Wolff, Gary H Rhodes, Robert Wallace Malone, Dennis A. Carson
  • Patent number: 7250502
    Abstract: The present invention provides formaldehyde dehydrogenase genes (FLD) from methylotrophic yeasts. The FLD structural genes confer resistance to formaldehyde and are therefore useful as a selectable marker in methylotrophic yeasts. The FLD promoter sequences are strongly and independently induced by either methanol as sole carbon source (with ammonium sulfate as nitrogen source) or methylamine as sole nitrogen source (with glucose as carbon source). Induction under either methanol, methylamine or both provides levels of heterologous gene expression comparable to those obtained with the commonly used alcohol oxidase I gene promoter (PAOX1). The FLD promoter of Pichia pastoris (PFLD1) is an attractive alternative to PAOX1 for expression of foreign genes in P. pastoris, allowing regulation by carbon (methanol) or nitrogen (methylamine) source within the same expression strain.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: July 31, 2007
    Assignee: Research Corporation Technologies, Inc.
    Inventor: James M. Cregg
  • Patent number: 7250293
    Abstract: A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary diploid human cells transformed by adenovirus E1 sequences either operatively linked on one or two DNA molecules, the sequences operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also, a cell line derived from PER.C6 that expresses functional Ad35-E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses. The cell lines can be used to produce human recombinant therapeutic proteins such as human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza, herpes simplex, rotavirus, and measles.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: July 31, 2007
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Menzo Havenga, Majid Mehtali